Jacobs Levy Equity Management Inc. Acquires New Holdings in NeuroPace, Inc. (NASDAQ:NPCE)

Jacobs Levy Equity Management Inc. purchased a new stake in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 57,096 shares of the company's stock, valued at approximately $639,000. Jacobs Levy Equity Management Inc. owned about 0.19% of NeuroPace at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after purchasing an additional 2,279 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in NeuroPace in the 4th quarter valued at $29,000. Financial Advocates Investment Management raised its position in NeuroPace by 27.8% during the 4th quarter. Financial Advocates Investment Management now owns 23,000 shares of the company's stock worth $257,000 after buying an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp raised its position in NeuroPace by 21.2% during the 4th quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company's stock worth $328,000 after buying an additional 5,133 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in NeuroPace by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock worth $3,615,000 after buying an additional 5,781 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on NPCE shares. JPMorgan Chase & Co. upped their price objective on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 14th. Cantor Fitzgerald restated an "overweight" rating and set a $17.00 price objective on shares of NeuroPace in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company upped their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

Insider Transactions at NeuroPace

In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the company's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the transaction, the insider now directly owns 3,238,199 shares of the company's stock, valued at $51,325,454.15. This represents a 4.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 22.20% of the company's stock.

NeuroPace Price Performance

Shares of NASDAQ:NPCE traded down $0.19 on Friday, reaching $17.68. 225,223 shares of the company were exchanged, compared to its average volume of 147,688. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. NeuroPace, Inc. has a 1-year low of $5.45 and a 1-year high of $18.98. The firm has a market cap of $579.89 million, a price-to-earnings ratio of -17.68 and a beta of 2.04. The company has a 50-day moving average of $12.65 and a 200-day moving average of $11.94.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $22.52 million for the quarter, compared to analysts' expectations of $21.85 million. Equities analysts forecast that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.